Search

Trioxsalen

It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. … Like other psoralens it causes photosensitization of the skin.

Epinastine

Epinastine is used for the prevention of itching associated with allergic conjunctivitis. … proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.

Altretamine

An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

Bromfenac

Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation.

Asparaginase Erwinia chrysanthemi

It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. … [L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase

Foscarnet

An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

Deutetrabenazine

The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound [A32046]. … In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046].

Morphine glucuronide

Recombinant stabilized RSV B prefusion F antigen

infants through six months of age. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

Blonanserin

As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.